These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11825939)

  • 1. Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells.
    Sarmati L; Nicastri E; Parisi SG; d'Ettorre G; Mancino G; Narciso P; Vullo V; Andreoni M
    J Clin Microbiol; 2002 Feb; 40(2):335-40. PubMed ID: 11825939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.
    Van Laethem K; Witvrouw M; Pannecouque C; Van Remoortel B; Schmit JC; Esnouf R; Kleim JP; Balzarini J; Desmyter J; De Clercq E; Vandamme AM
    AIDS; 2001 Mar; 15(5):553-61. PubMed ID: 11316991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
    Lafeuillade A; Poggi C; Hittinger G; Chadapaud S
    HIV Med; 2001 Oct; 2(4):231-5. PubMed ID: 11737402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.
    Coakley EP; Gillis JM; Hammer SM
    AIDS; 2000 Jan; 14(2):F9-15. PubMed ID: 10708277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy.
    Brindeiro PA; Brindeiro RM; Mortensen C; Hertogs K; De Vroey V; Rubini NP; Sion FS; De Sá CA; Machado DM; Succi RC; Tanuri A
    J Clin Microbiol; 2002 Dec; 40(12):4512-9. PubMed ID: 12454144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.
    Pellegrin I; Segondy M; Garrigue I; Izopet J; Montes B; Pellegrin JL; Reynes J; Massip P; Puel J; Fleury H
    J Acquir Immune Defic Syndr; 2000 Dec; 25(5):465-6. PubMed ID: 11141248
    [No Abstract]   [Full Text] [Related]  

  • 8. Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected patients in Korea.
    Cho YK; Sung H; Ahn SH; Bae IG; Woo JH; Won YH; Kim DG; Kang MW
    J Clin Microbiol; 2002 Apr; 40(4):1319-25. PubMed ID: 11923351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.
    Hertogs K; Bloor S; De Vroey V; van Den Eynde C; Dehertogh P; van Cauwenberge A; Stürmer M; Alcorn T; Wegner S; van Houtte M; Miller V; Larder BA
    Antimicrob Agents Chemother; 2000 Mar; 44(3):568-73. PubMed ID: 10681319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
    Picard V; Angelini E; Maillard A; Race E; Clavel F; Chêne G; Ferchal F; Molina JM
    J Infect Dis; 2001 Sep; 184(6):781-4. PubMed ID: 11517441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordance between genotypic resistance and pseudovirus phenotypic resistance in AIDS patients after long-term antiretroviral therapy and virological failure.
    Yang J; Geng W; Zhang M; Han X; Shang H
    J Basic Microbiol; 2014 Oct; 54(10):1120-5. PubMed ID: 24338739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
    Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
    Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ; Chappey C; Parkin NT; Miller MD
    Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
    Miller V; Ait-Khaled M; Stone C; Griffin P; Mesogiti D; Cutrell A; Harrigan R; Staszewski S; Katlama C; Pearce G; Tisdale M
    AIDS; 2000 Jan; 14(2):163-71. PubMed ID: 10708287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
    AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
    Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
    AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study on mutations and antiretroviral therapy (SMART): preliminary results.
    Gianotti N; Moretti F; Tambussi G; Racca S; Presi S; Crucianelli R; Carrera P; Ferrari M; Lazzarin A
    Antivir Ther; 1999; 4 Suppl 3():65-9. PubMed ID: 16021873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.